Business Context and Reporting Period
This Form 8-K reports on the 2014 Annual Meeting of Stockholders held by TherapeuticsMD, Inc. on June 11, 2015. The filing details the voting results for four specific proposals submitted to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's 10-K or 10-Q filings for financial performance data.
Material Changes and Voting Results
Stockholders voted on and approved the following four proposals:
- Proposal 1 (Election of Directors): Ten directors were elected to serve until the next annual meeting. All nominees received significant "For" votes with zero "Against" votes.
- Proposal 2 (Executive Compensation): A non-binding advisory vote on executive compensation for fiscal 2014 was approved. Approximately 95.6% of votes cast were "For" (122,028,405) versus 2,996,726 "Against".
- Proposal 3 (Auditor Ratification): The appointment of Grant Thornton, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015, was ratified with overwhelming support (155,310,072 "For" votes).
- Proposal 4 (Authorized Share Increase): An amendment to the articles of incorporation was approved to increase the number of authorized common shares from 250,000,000 to 350,000,000 shares. This received 149,481,490 "For" votes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the administrative outcome of the shareholder meeting.
Key Facts for Investor Verification
- Verify the impact of the increased authorized share count (from 250M to 350M) on potential future dilution.
- Confirm the tenure of the newly elected board of directors.
- Review the 2015 Proxy Statement (filed April 30, 2015) for detailed background on the executive compensation advisory vote.
- Note that Grant Thornton, LLP is the confirmed auditor for the fiscal year ending December 31, 2015.